Global CAR T cell therapy market is estimated to grow at a CAGR of 12.0% during the forecast period. Chimeric antigen receptor (CAR) T-cell therapy treats certain cancers by turning T-lymphocytes or T-cells into more efficient cancer-fighting machines. In the past three years, the number of cancer survivors living in the US increased by more than a million, reaching greater than 18 million as of January 2022, according to the American Association for Cancer Research (AACR). The increasing focus on clinical trials for CAR T cell therapy is providing enormous opportunities for the global CAR T cell therapy market.
According to the Ministry of Science & Technology, in June 2021 IIT Bombay team and cancer care in India as the first CAR-T cell therapy was done at the Bone Marrow Transplant unit at ACTREC, Tata Memorial Center in Mumbai. The CAR-T cells were designed and manufactured at the Bioscience and Bioengineering (BSBE) department of IIT Bombay. This is a “first in India” gene therapy in the early phase pilot clinical trial and the dedicated efforts and excellent collaboration between IIT Bombay and Tata Memorial Hospital, Mumbai. The central government’s National Biopharma Mission-BIRAC has approved 2.6 million to the team for conducting a first-in-human phase-1/2 clinical trial of the CAR-T cells. This work is partly supported by the BIRAC-PACE scheme. The TMC-IIT Bombay team is further supported to extend this project for conducting Phase I/II trial of their CAR-T product by DBT/BIRAC, through National Biopharma Mission.
Browse the full report description of “CAR T Cell Therapy Market Size, Share & Trends Analysis Report, By Application (Non-Hodgkin Lymphoma, Acute Lymphocytic Leukemia, and Others), By Target Antigen (CD19, CD22, and Others) Forecast Period (2022-2030)” at https://www.omrglobal.com/industry-reports/car-t-cell-therapy-market
Moreover, increasing FDA approval and new development for cancer treatment further drive market growth. For instance, in May 2022, The US Food and Drug Administration (FDA) expanded its approval for a personalized cellular therapy developed at the University of Pennsylvania’s Abramson Cancer Center, for the treatment of adults with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. The accelerated approval was granted to Novartis for the chimeric antigen receptor (CAR) T-cell therapy Kymriah (tisagenlecleucel), making it the third indication for the nation’s first personalized cellular therapy for cancer. It remains the only CAR-T cell therapy approved for both adult and pediatric patients.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Application
o By Target Antigen
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Novartis International AG, Gilead Sciences, Inc., Pfizer, Inc., Bristol-Myers Squibb Co., Takeda Pharmaceutical Co. Ltd., and others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global CAR T Cell Therapy Market Report Segment
By Application
By Target Antigen
Global CAR T Cell Therapy Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/car-t-cell-therapy-market